With diverse management experience in the life science industry and over 100 years of collective experience, our leadership team is ready to change the shape of medical research and practice.
Keith Murphy, Chairman and Chief Executive Officer
Mr. Murphy has more than 20 years of experience in biotechnology, including co-founding Organovo in 2007 and serving in Product Strategy and Director of Process Development roles at Amgen. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.
Craig Kussman, Chief Financial Officer
Mr. Kussman has more than 20 years of financial and general management experience in the healthcare sector. He is an accomplished executive with extensive financial, strategic and operational experience in technology and biotechnology companies ranging from large public multinational corporations to private start-ups. Mr. Kussman spent the prior 2 years at ALPHAEON® Corporation as CFO, where he helped raise over $150 million in equity and debt capital, as well as complete five acquisitions to help the company scale rapidly. Prior to this role, Mr. Kussman served as CFO at XIFIN, Inc., where he helped lead XIFIN’s private equity recapitalization with GTCR. In addition, Mr. Kussman served as CFO and co-CEO at Breach Security, before successfully negotiating its sale to Trustwave, and as CFO and senior vice president of corporate development for Ascenta Therapeutics, a development stage biopharmaceutical company, leading the company’s $52 million Series C financing. Kussman has also held senior executive positions at Discovery Partners International, Inc., SYNAVANT Inc., Cognizant Corp., and IMS Health, in addition to various financial and corporate development positions at The Dun & Bradstreet Corporation. Kussman earned a B.A. cum laude in economics and mathematics from Pomona College and an M.B.A. with distinction in Finance from the Wharton School of Business at the University of Pennsylvania.
Sharon Collins Presnell, Ph.D., Chief Scientific Officer, Organovo & President, Samsara
Dr. Presnell has more than 18 years of experience leading product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research and was responsible for the discovery and early development of Tengion’s Neo-Kidney Augment™ technology, which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a Ph.D. in pathology from the Medical College of Virginia.
Eric Michael David, M.D., J.D., Chief Strategy Officer and Executive Vice President of Preclinical Development
Dr. David has more than 15 years of experience in biomedical research and product development. He played a critical role in the commercial translation of 3D bioprinting as a founder and early director of Organovo, Inc. Dr. David was most recently associate partner at the consultancy McKinsey & Company, where he served private equity, pharmaceutical, biotech, diagnostic, and medical device clients to support pipeline and R&D strategy, as well as market entry strategy. Prior to his time at McKinsey, Dr. David served as a freelance consultant to the Department of Health and Human Services in the use of genomic technologies for early detection of pathogens for public health preparedness. He completed his residency in Internal Medicine at New York Presbyterian Hospital, where he served as Assistant Chief Resident and received the Dick Bowman Award for scientific endeavor and dedication to patient care. He was also Assistant Professor at The Rogosin Institute, adjunct faculty at The Rockefeller University, and a lecturer in Medicine at Weil Cornell Medical College. He received his M.D. from Columbia University College of Physicians and Surgeons, his J.D. from Columbia University School of Law, and a B.A. in Physics and Fine Arts from Amherst College. He is board certified in Internal Medicine and admitted to the Bar in New York State.
Jennifer Kinsbruner Bush, J.D., General Counsel, Corporate Secretary and Compliance Officer
Ms. Bush has more than 15 years of intellectual property, corporate legal, regulatory, compliance, and transactional experience. Prior to joining Organovo, Ms. Bush held positions of increasing responsibility at Broadcom Corp., where she was most recently Associate General Counsel. Before joining Broadcom, Ms. Bush served as Associate General Counsel of DivX, Inc. prior to its acquisition by Sonic Solutions in October 2010. Earlier in her career, Ms. Bush was a Principal at Fish & Richardson, from 2001 to January 2010, where she represented clients focused on a variety of technologies, including in the areas of medical devices, life sciences, software, and consumer products. Ms. Bush received a J.D. from Yale Law School and an A.B. in history and Latin American studies from Princeton University.
Susan Daugherty, Vice President, Human Resources
Ms. Daugherty has more than 30 years of combined human resources and industry experience within various pharmaceutical, medical device, retail, and technology companies. Most recently, Ms. Daugherty was with Onyx Pharmaceuticals in a Global Human Resources Business Partner role, supporting R&D, Technical and Clinical Operations, Drug Safety, Quality, and Regulatory organizations. From May 2006 through October 2010, Ms. Daugherty was Vice President, Human Resources with Carefusion/Cardinal Health where she supported three global medical device businesses. Ms. Daugherty holds a B.S. in consumer economics from the University of Massachusetts.
Paul Gallant, General Manager
Mr. Gallant has more than 20 years of management and R&D experience in the drug discovery industry, most recently serving as chief operating officer for DiscoveRx, a global scientific product and services company. As Chief Operating Officer at DiscoveRx, Mr. Gallant was responsible for the company’s largest business unit, drug discovery services. Mr. Gallant formerly served as senior director at Ambit Pharmaceuticals, acquired by DiscoveRx in 2010, where he led the development and commercialization for the KINOMEscan platform. The world’s largest commercial kinase screening panel, KINOMEscan became a key element of DiscoveRx’s offering post-acquisition. Mr. Gallant has also led R&D and service teams at Amgen, Millennium Pharmaceuticals, Cubist Pharmaceuticals and Massachusetts General Hospital. He earned a B.A. in biology from Colby College.